REVOLUTION MEDICINES INC(NASDAQ:RVMD) stock News

RVMD Latest News, Press Relases and Analysis

All

Press Releases

9 days ago - By: Revolution Medicines, Inc.

Revolution Medicines Announces Key Leadership Additions, including Alan Sandler, M.D. as Chief Development Officer

a month ago - By: Benzinga

Analysts Raise Price Targets Following Strong Data From Revolution Medicines' Pancreatic Cancer Drug

a month ago - By: Benzinga - Mentions: XRTX RNA KZIA APM ...

12 Health Care Stocks Moving In Thursday's Pre-Market Session

a month ago - By: Revolution Medicines, Inc.

Revolution Medicines Shares New Clinical Results Supporting Initiation of RASolute 303, a Global Phase 3 Registrational Trial of Daraxonrasib in First Line Metastatic Pancreatic Ductal Adenocarcinoma

a month ago - By: Yahoo Finance - Mentions: RPRX GILD

Royalty Pharma plc (RPRX) Strikes $2B Partnership with Revolution Medicines

2 months ago - By: Revolution Medicines, Inc.

Revolution Medicines Reports Second Quarter 2025 Financial Results and Update on Corporate Progress

2 months ago - By: Revolution Medicines, Inc.

Revolution Medicines to Report Financial Results for Second Quarter 2025 After Market Close on August 6, 2025

3 months ago - By: Revolution Medicines, Inc.

Revolution Medicines Announces Publication of a Peer-Reviewed Research Paper in Science on the Discovery and Development of Zoldonrasib, a RAS(ON) G12D-Selective Inhibitor

3 months ago - By: Yahoo Finance - Mentions: GS

Revolution Medicines (RVMD) Gets Initiated With a New Buy Rating at Goldman Sachs

3 months ago - By: Revolution Medicines, Inc.

Revolution Medicines and Iambic Announce Technology and Research Collaboration Using Iambic’s AI Discovery Tools to Pursue New Drug Candidates

3 months ago - By: Yahoo Finance - Mentions: PRMB

Oppenheimer Reaffirms Outperform on Revolution Medicines, Cites PDAC and NSCLC Trial Progress

3 months ago - By: Yahoo Finance - Mentions: PRMB

Primo Brands Stock Backed by Barclays on Hydration Market Strength

3 months ago - By: Summit Therapeutics Inc. - Mentions: SMMT

Revolution Medicines and Summit Therapeutics Enter Into Clinical Collaboration to Evaluate Combinations of Three RAS(ON) Inhibitors With Ivonescimab in RAS Mutant Tumors

3 months ago - By: Revolution Medicines, Inc.

Revolution Medicines and Summit Therapeutics Enter into Clinical Collaboration to Evaluate Combinations of Three RAS(ON) Inhibitors with Ivonescimab in RAS Mutant Tumors

4 months ago - By: Stocktwits - Mentions: RPRX VTI

Revolution Medicines To Get Up To $2B For Development Of Cancer Drug From Royalty Pharma

4 months ago - By: Revolution Medicines, Inc.

Revolution Medicines Enters Into $2 Billion Flexible Funding Agreement with Royalty Pharma to Support Global Development and Commercialization of RAS(ON) Inhibitor Portfolio for Patients with RAS-Addicted Cancers

4 months ago - By: Revolution Medicines, Inc.

Revolution Medicines Announces FDA Breakthrough Therapy Designation for Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer with KRAS G12 Mutations

5 months ago - By: Revolution Medicines, Inc.

Revolution Medicines Announces First Patient Dosed in Phase 3 Clinical Trial Evaluating Daraxonrasib in Previously Treated Patients with RAS Mutant Non-Small Cell Lung Cancer

5 months ago - By: Revolution Medicines, Inc.

Revolution Medicines Reports First Quarter 2025 Financial Results and Update on Corporate Progress

5 months ago - By: Revolution Medicines, Inc.

Revolution Medicines to Report Financial Results for First Quarter 2025 After Market Close on May 7, 2025

5 months ago - By: Revolution Medicines, Inc.

Revolution Medicines Presents Initial Data from Zoldonrasib (RMC-9805) Study in Patients with KRAS G12D Mutant Non-Small Cell Lung Cancer at the 2025 AACR Annual Meeting

6 months ago - By: Revolution Medicines, Inc.

Revolution Medicines to Deliver Multiple Presentations at the 2025 American Association for Cancer Research (AACR) Annual Meeting

6 months ago - By: Yahoo Finance

Revolution Medicines (RVMD): The Best Debt Free Mid Cap Stock to Buy Now

6 months ago - By: Revolution Medicines, Inc.

REVOLUTION MEDICINES INC (RVMD) Stock News

RVMD Latest News, Press Relases and Analysis

Revolution Medicines Announces Key Leadership Additions, including Alan Sandler, M.D. as Chief Development Officer

Analysts Raise Price Targets Following Strong Data From Revolution Medicines' Pancreatic Cancer Drug

12 Health Care Stocks Moving In Thursday's Pre-Market Session

Revolution Medicines Shares New Clinical Results Supporting Initiation of RASolute 303, a Global Phase 3 Registrational Trial of Daraxonrasib in First Line Metastatic Pancreatic Ductal Adenocarcinoma

Royalty Pharma plc (RPRX) Strikes $2B Partnership with Revolution Medicines

Revolution Medicines Reports Second Quarter 2025 Financial Results and Update on Corporate Progress

Revolution Medicines to Report Financial Results for Second Quarter 2025 After Market Close on August 6, 2025

Revolution Medicines Announces Publication of a Peer-Reviewed Research Paper in Science on the Discovery and Development of Zoldonrasib, a RAS(ON) G12D-Selective Inhibitor

Revolution Medicines (RVMD) Gets Initiated With a New Buy Rating at Goldman Sachs

Revolution Medicines and Iambic Announce Technology and Research Collaboration Using Iambic’s AI Discovery Tools to Pursue New Drug Candidates

Oppenheimer Reaffirms Outperform on Revolution Medicines, Cites PDAC and NSCLC Trial Progress

Primo Brands Stock Backed by Barclays on Hydration Market Strength

Revolution Medicines and Summit Therapeutics Enter Into Clinical Collaboration to Evaluate Combinations of Three RAS(ON) Inhibitors With Ivonescimab in RAS Mutant Tumors

Revolution Medicines and Summit Therapeutics Enter into Clinical Collaboration to Evaluate Combinations of Three RAS(ON) Inhibitors with Ivonescimab in RAS Mutant Tumors

Revolution Medicines To Get Up To $2B For Development Of Cancer Drug From Royalty Pharma

Revolution Medicines Enters Into $2 Billion Flexible Funding Agreement with Royalty Pharma to Support Global Development and Commercialization of RAS(ON) Inhibitor Portfolio for Patients with RAS-Addicted Cancers

Revolution Medicines Announces FDA Breakthrough Therapy Designation for Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer with KRAS G12 Mutations

Revolution Medicines Announces First Patient Dosed in Phase 3 Clinical Trial Evaluating Daraxonrasib in Previously Treated Patients with RAS Mutant Non-Small Cell Lung Cancer

Revolution Medicines Reports First Quarter 2025 Financial Results and Update on Corporate Progress

Revolution Medicines to Report Financial Results for First Quarter 2025 After Market Close on May 7, 2025

Revolution Medicines Presents Initial Data from Zoldonrasib (RMC-9805) Study in Patients with KRAS G12D Mutant Non-Small Cell Lung Cancer at the 2025 AACR Annual Meeting

Revolution Medicines to Deliver Multiple Presentations at the 2025 American Association for Cancer Research (AACR) Annual Meeting

Revolution Medicines (RVMD): The Best Debt Free Mid Cap Stock to Buy Now

Revolution Medicines to Participate in April 2025 Investor Conferences